gefitinib
美 
英
例句
Gefitinib failed to show superiority to placebo as second- or third-line treatment, but it has been shown to be non inferior to docetaxel.
吉非替尼在二线和三线治疗中与安慰剂相比无优势，但其作用不逊于多西他赛。
However, this specific mutation did not cause acne, another side of effect of gefitinib.
然而，这种特异性的突变不会导致gefitinib的另一个副作用：痤疮。
Gefitinib may have inhibitory effects against bone resorption as well as antitumor effects.
吉非替尼可能会抑制对骨吸收以及抗肿瘤作用。
Being female was also significantly associated with response to gefitinib.
病人是女性也与对吉非替尼有反应显著相关。
The acute toxicity of gefitinib up to 500 mg in clinical studies has been low.
急性毒性吉非替尼多达500毫克的临床研究一直很低。
Doctor, the profile that you just read is actually for (gefitinib) IRESSA.
医生，刚才您所阅读的简介其实就是（吉非替尼）易瑞沙。
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
肺癌中表皮生长因子受体突变：吉非替尼治疗的临床反应。
What are your first thoughts about the potential indication for IRESSA (gefitinib) IRESSA? Do you agree? Do you think it is appropriate?
对于易瑞沙（吉非替尼）的潜在迹象有什么想法？您是否赞同？您认为它是否合适？
The advantages that Gefitinib treated non-small cell lung cancer and the existing problems were expounded in this thesis.
本文针对吉非替尼靶向治疗非肺癌小细胞肺癌中的优点和所面临的问题进行阐述。
We reported cases of non-small-cell lung cancer who had dramatic improvements of pathologic fractures with gefitinib.
我们报告的非小细胞肺癌有显着改善谁的病理性骨折与吉非替尼。
Results 31 patients with Gefitinib associated skin rash were divided Wind-Heat type, Damp-Heat type, Blood-Heat type and Blood-XU type.
结果31例吉非替尼相关皮疹患者，辨证分型为：风热型、湿热型、血热型、阴虚型；
Therefore, it would also provide necessary evidence to test EGFR mutations for the use of Gefitinib in CRCs.
因此，检测大肠癌EGFR外显子突变也为将吉非替尼疗应用于大肠癌提供理论依据。
A phase II study evaluated gefitinib and docetaxel as second-line therapy .
一项II期临床试验对gefitinib和多西他赛作为二线治疗方案进行检验。
Clinical observation on advanced stage adenocarcinoma of lung treated with gefitinib after failure of chemotherapy
吉非替尼治疗化疗失败晚期肺腺癌的临床观察
Gefitinib in patients with advanced refractory small cell lung cancer contemporaneous with superior vena cava syndrome
吉非替尼治疗晚期难治性小细胞肺癌合并急性上腔静脉综合征
Efficacy of Gefitinib on Chinese Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: a Clinical Trial
吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究
Overview of relationship between EGFR gene mutation and efficacy and acquired drug resistance of gefitinib
EGFR基因突变与吉非替尼的疗效和获得性耐药关系的研究概况
Effect of EGFR inhibitor gefitinib on proliferation and apoptosis of hepatocellular carcinoma cells
EGFR抑制剂吉非替尼对肝癌细胞增殖和凋亡的影响
Preliminary observation of gefitinib in salvage treatment of patients with previouslytreated, advanced non-small cell lung cancer
吉非替尼挽救性治疗晚期非小细胞肺癌的初步观察
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor
表皮生长因子受体酪氨酸激酶抑制剂吉非替尼
Efficacy of Gefitinib on Advanced Non-small Cell Lung Cancer of Bilateral Diffuse or Unilateral Giant Mass Type
吉非替尼治疗不同类型晚期非小细胞肺癌患者的疗效比较
Oral gefitinib is small molecular targeted therapeutic drug
口服小分子靶向治疗药物吉非替尼
Gefitinib in elderly and unfit patients affected non-small-cell lung cancer
吉非替尼在老年和行为状态差的非小细胞肺癌患者中的应用
Targeted therapy with gefitinib for non-small cell lung cancer
吉非替尼靶向治疗非小细胞肺癌
Progress in research of gefitinib, an anticancer drug
抗肿瘤药物吉非替尼的研究进展
An improved synthetic process for gefitinib
吉非替尼的合成工艺改进
Gefitinib in the treatment of advanced, refractory non-small cell lung cancer: EAP study in 53 patients
吉非替尼治疗晚期非小细胞肺癌53例临床观察
Progress in therapy of gefitinib for Non-small cell lung cancer
吉非替尼治疗非小细胞肺癌的研究进展
